Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
28 avr. 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen Announces Closing of $4.75 Million Private Placement
25 mars 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s...
Histogen Announces $4.75 Million Private Placement
23 mars 2022 08h00 HE
|
Histogen Inc
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s...
Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
10 mars 2022 16h05 HE
|
Histogen Inc
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase...
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
03 mars 2022 16h15 HE
|
Histogen Inc
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Closing of $3.5 Million Private Placement
21 déc. 2021 18h19 HE
|
Histogen Inc
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s...
Histogen Announces $3.5 Million Private Placement
16 déc. 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s...
Histogen Reports Third Quarter 2021 Earnings and Provides Business Update
10 nov. 2021 16h05 HE
|
Histogen Inc
Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee On-Going with Top-Line Data Expected in the Second Half of 2022 IND Filing for HST 004 for Spinal Disc Repair Anticipated in the...
Histogen Announces CEO Transition
08 nov. 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference
02 nov. 2021 08h00 HE
|
Histogen Inc
Phase 1 Study in Mild COVID-19 Patients Demonstrated a Favorable Safety and Tolerability Profile and Statistically Significant Clinical Symptom and Biomarker Improvements Additional Analysis...